Semaglutide Results at Three Months: What the Evidence Shows

Week 12 arrived, and the scales haven't moved as much as you hoped

You started your first pen with reasonable expectations. The first few weeks brought nausea, a noticeably smaller appetite, and a few kilograms coming off fairly quickly. Now you're at the three-month mark and you're wondering whether what you've lost is normal, or whether something has stalled.

Here's the honest picture. In the STEP 1 trial, weight loss at 12 weeks was meaningful but not complete, participants were still titrating at that point. The 2.4mg maintenance dose is reached after roughly five months of stepping up from 0.25mg, so if you've been on semaglutide for three months you may only recently have moved past the 1mg mark. The dose you're on shapes the result you're seeing. That's not a flaw in the medicine; it's the titration schedule working as designed, giving your body time to adjust at each level.

The full picture of what semaglutide results look like over time shows that the rate of loss tends to slow after the first couple of months, then picks up again as the dose increases. A plateau in month three is common. It doesn't mean the treatment isn't working.

One practical note: keeping the pen in the fridge door where you'll see it each week makes the routine harder to break, consistency across doses matters more than any single week's reading on the scale.

What the trial data actually says about the 12-week window

The STEP 1 trial is the most cited piece of evidence for semaglutide's weight-loss effect, and it's worth understanding what it does and doesn't tell us about three months specifically. At 68 weeks, participants on 2.4mg semaglutide lost an average of around 15% of their body weight. The weight-loss curve in trials like this is not linear, it accelerates during dose escalation, then moderates as participants reach maintenance, then continues more gradually.

Published analyses of the STEP programme suggest that by week 12 a loss of roughly 5% body weight is a reasonable indicator that treatment is progressing well. Those who lost at least 5% by that point tended to go on to stronger results at the end of the trial. Those who hadn't lost 5% by week 16 were less likely to achieve substantial loss long-term, which is why NICE's guidance on semaglutide (TA875) includes a review point after six months at maintenance dose, not three months. Prescribers aren't looking for dramatic results at 12 weeks; they're looking for a clear directional signal.

If you're curious how the first month of treatment tends to feel compared to where you are now, reading about semaglutide one month results gives useful context for how quickly things can shift before titration fully takes hold. The two months in between are where titration does most of its work, and what happens around month two often explains why month three looks the way it does.

Side effects at three months: what's normal, what to watch

Gastrointestinal effects (nausea, loose stools, constipation, reflux) are most common in the days following a dose increase. By month three, many people find these have largely settled, particularly if titration has been gradual. If you've recently moved to a higher dose, a brief return of nausea is expected and usually short-lived.

Fatigue and headache can appear early in treatment and tend to ease. Injection-site reactions (mild redness or bruising) are usually minor and resolve quickly; rotating between the abdomen, thigh, and upper arm helps.

Two things warrant prompt attention rather than waiting. Severe stomach pain that reaches through to your back, especially with vomiting, should be assessed the same day, the MHRA has flagged acute pancreatitis as an infrequent but serious risk with GLP-1 medicines, and the MHRA's Yellow Card scheme is the right place to report any suspected side effect. Persistent dehydration from vomiting or diarrhoea also needs medical input quickly. Neither of these is common, but both matter.

For a question our prescribers hear regularly: if side effects have made the last few weeks difficult, that's a clinical conversation, not something to manage alone. Dose holds and slower titration are both legitimate options, a prescriber decides, based on your individual response.

Where to go from here if you're three months in

Three months is early enough that your trajectory still has a long way to run. The timeline for Wegovy's full effect extends well beyond the 12-week mark, the STEP 1 trial ran for 68 weeks, and the steepest part of the curve came after participants reached 1.7mg and 2.4mg.

If you haven't yet reached your maintenance dose, your results so far are a starting point. If you have reached 2.4mg and feel three months in isn't yielding what you expected, that conversation belongs with your prescriber. There is now also a 7.2mg formulation of Wegovy, approved by the MHRA in April 2026, though whether that's relevant to your situation is a clinical assessment.

Semaglutide works best alongside consistent changes to food quality and physical activity. Not dramatic restriction, adequately nourishing yourself while appetite is suppressed takes some deliberate attention. Protein intake, hydration, and not skipping meals are practical priorities at this stage.

If you're weighing up your longer-term options, how Wegovy is priced privately in the UK is one practical factor, though for a prescription medicine, safety of supply and consistent clinical oversight are the measures that count most. If you'd like to begin treatment or discuss where you are in your current course, start a free consultation with our prescribers, your answers are reviewed the same day by a real clinician, not software.